Pfizer and BioNTech: Vaccine 95% effective in final efficacy analysis of phase 3 trial
|Pfizer Inc said on Wednesday that the final efficacy analysis of phase 3 trial of the coronavirus vaccine it develops with BioNTech has shown to be 95% effective, as reported by Reuters.
Additional takeaways
"Efficacy of COVID-19 vaccine was consistent across age, race and ethnicity demographics."
"Planning to file for US emergency use authorization of COVID-19 vaccine within days."
"Concluded phase 3 study with 170 confirmed cases of covid; 162 of those cases were in the placebo arm."
"9 of the severe COVID-19 cases were in the placebo group, 1 was in the vaccine group."
"10 severe cases of COVID-19 were observed in the trial."
"Observed efficacy of COVID-19 vaccine in adults over 65 was over 94%."
"No serious safety concerns observed in the COVID-19 vaccine trial."
"Side effects were mostly mild to moderate and cleared up quickly."
"The only significant side effect greater than 2% in frequency was fatigue at 3.7%."
"Still expecting to make up to 50 million doses this year, 1.3 billion in 2021."
Market reaction
The S&P 500 Futures edged higher on this report and was last seen gaining 0.35% on the day at 3,619.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.